LLYEli Lilly and CompanyRunning, no new patients
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 5,637 (final count)
- Started
- Jul 12, 2017
- Main results expected
- Mar 16, 2020
- Fully finished
- May 2029
- Results posted
- Apr 9, 2021
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Disease Free Survival (IDFS)
Measured over: Baseline to Recurrence or Death from Any Cause (Up to 32 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03155997 · record last updated 2026-04-24 · checked 2026-11-09 15:36 UTC